You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti NR2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)

Not yet recruiting
  • 18F-HER2 PET
  • 18F-HER2 PET
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of med
Aug 2, 2023

Macular Edema Due to Type 2 Diabetes Trial in Hangzhou (Anti-VEGF, subthreshold micropulse laser)

Recruiting
  • Macular Edema Due to Type 2 Diabetes Mellitus
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Feb 26, 2023

Long COVID Trial (Nicotinamide Riboside (NR), Mind-body reprocessing therapy (MBRT), Care as usual)

Not yet recruiting
  • Long COVID
  • Nicotinamide Riboside (NR)
  • +3 more
  • (no location specified)
Jan 26, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Hearing Loss Trial in Oldenburg (Measures of Standard Noise Reduction NR1, Measures of Noise Reduction Principle NR2, Measure of

Completed
  • Hearing Loss
  • Measures of Standard Noise Reduction NR1
  • +2 more
  • Oldenburg, Niedersachsen, Germany
    Hörzentrum Oldenburg gGmbH
Nov 16, 2022

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Anti-aging Trial in Tours (Anti-aging cosmetic care product)

Completed
  • Anti-aging
  • Anti-aging cosmetic care product
  • Tours, France
    Spincontrol
May 31, 2023

Anti-Argonaute Antibodies for Diagnosis of Sensory

Completed
  • Autoimmune Diseases
  • Diagnosis of sensitive neuronopathy - phase 1
  • +4 more
  • Saint-Étienne, France
    CHU Saint-Etienne
Jul 27, 2023

Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

Recruiting
  • Breast Neoplasm Female
  • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
  • Beijing, Beijing, China
  • +1 more
Jul 31, 2023

Trial

Not yet recruiting
  • Leber Hereditary Optic Neuropathy (LHON)
  • NR082 Injection
  • Injection needle
  • (no location specified)
Jan 30, 2023

Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))

Active, not recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +75 more
Oct 4, 2022

Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

Not yet recruiting
  • Esophagus Cancer
  • +4 more
  • Intravenous injection of P-IL-2
  • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
  • (no location specified)
Apr 24, 2023

NSCLC Trial in Jette (68GaNOTA-Anti-MMR-VHH2)

Recruiting
  • Non-small Cell Lung Cancer
  • Jette, Brussel, Belgium
    Universitair Ziekenhuis Brussel
Jun 27, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster

Terminated
  • Anti-SARS-CoV-2 Antibody Response
  • blood and saliva samples will be taken
  • Graz, Austria
    Medizinische Universität Graz, Klinische Abteilung für Rheumatol
Jan 9, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

COVID-19, SARS CoV 2 Infection Trial in Orléans (Collection of biological samples)

Not yet recruiting
  • COVID-19
  • SARS CoV 2 Infection
  • Collection of biological samples
  • Orléans, France
    Centre Hospitalier Régional d'Orléans, France
Jul 21, 2022

Metastatic Pancreatic Carcinoma Trial in Providence (CAR2 Anti-CEA CAR-T cells)

Terminated
  • Metastatic Pancreatic Carcinoma
  • CAR2 Anti-CEA CAR-T cells
  • Providence, Rhode Island
    Roger Williams Medical Center
Jan 12, 2023

Rheumatoid Arthritis Trial in La Jolla (Diet 1, Diet 2)

Recruiting
  • Rheumatoid Arthritis
  • Diet 1
  • Diet 2
  • La Jolla, California
    UCSD
Jul 19, 2022

NSCLC Trial (Dupilumab, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Dupilumab
  • Cemiplimab
  • (no location specified)
Oct 12, 2023

Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)

Recruiting
  • Solid Tumor
  • TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
  • Aldesleukin
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 31, 2023

Healthy Volunteers Trial in Milano (Berry extract 1, Berry extract 2, Placebo)

Not yet recruiting
  • Healthy Volunteers
  • Berry extract 1
  • +2 more
  • Milano, Italy
    Complife Italia srl
Sep 4, 2023